An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

NCT00219232 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
868
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis